Zobrazeno 1 - 10
of 97
pro vyhledávání: '"Zakharia, Y. A."'
Autor:
Petronek, M.S., Stolwijk, J.M., Murray, S.D., Steinbach, E.J., Zakharia, Y., Buettner, G.R., Spitz, D.R., Allen, B.G.
Publikováno v:
In Redox Biology June 2021 42
Autor:
Jindal, T., Jiang, C., Alhalabi, O., Nguyen, C.B., Nizam, A., Basu, A., Zakharia, Y., Bilen, M.A., Brown, J., Milowsky, M., Kilari, D., Emamekhoo, H., Hoimes, C.J., Shah, S., Gupta, S., Grivas, P., Bellmunt, J., Campbell, M.T., Alva, A., Koshkin, V.S.
Publikováno v:
In ESMO Open February 2024 9 Supplement 1
Publikováno v:
Drug Design, Development and Therapy, Vol Volume 11, Pp 1175-1182 (2017)
Vyshak Alva Venur,1 Monika Joshi,2 Kenneth G Nepple,3 Yousef Zakharia1 1Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Hematology-Onco
Externí odkaz:
https://doaj.org/article/6204999cf7744432a7567e2c34b58f28
Autor:
Nizam, A., Zhang, L., Jiang, C.Y., Nguyen, C.B., Bakaloudi, D.R., Bilen, M.A., Coelho Barata, P.M., Zakharia, Y., Milowsky, M.I., Kilari, D., Hoimes, C.J., Khaki, A.R., Emamekhoo, H., Gupta, S., Grivas, P., Bellmunt, J., Alva, A.S., Campbell, M.T., Alhalabi, O., Koshkin, V.S.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S1142-S1142
1709P Outcomes with novel combinations in non-clear cell renal cell carcinoma (nccRCC): ORACLE study
Autor:
Kilari, D., Szabo, A., Bilen, M.A., Ged, Y., Maughan, B.L., Hwang, C., McManus, H., Coelho Barata, P.M., Desai, A., Zakharia, Y., Emamekhoo, H., Tripathi, A., Rose, T., Ghatalia, P., Reimers, M.A., Heath, E., King, J.M., Rini, B.I., Brugarolas, J., McKay, R.R.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S1024-S1025
Autor:
Jonasch, E., McGregor, B.A., Msaouel, P., Logan, T., Hall, E.T., Bilen, M.A., Falchook, G.S., Shuch, B., Zakharia, Y., Hauke, R., Gordon, M., Naqash, A-R., Ryan, C.W., Srinivasan, R., Xiao, J., Sun, W., Esguerra, M., Lu, G., Lager, J., Choueiri, T.K.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S1011-S1012
Autor:
Thapa, B., Henderson, N., Tagawa, S.T., Hwang, C., Sokolova, A.O., Bilen, M.A., Coelho Barata, P.M., Nguyen, C.B., Tripathi, A., Ayanambakkam, A., Graham, L.S., Zakharia, Y., Koshkin, V.S., Heath, E., Dorff, T.B., Armstrong, A.J., McKay, R.R., Alva, A.S., Schweizer, M., Kilari, D.
Publikováno v:
In Annals of Oncology September 2024 35 Supplement 2:S991-S991
Background: Immune checkpoint inhibitors (ICI) improve overall survival (OS) in patients with locally advanced, unresectable, or metastatic urothelial carcinoma (aUC), but response rates can be modest. We compared outcomes between patients with and w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::c678f97dc0fafb034716000807e17907
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118762
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3118762
Objectives: To compare clinical outcomes between patients with locally advanced (unresectable) or metastatic urothelial carcinoma (aUC) in the upper and lower urinary tract receiving immune checkpoint inhibitors (ICIs). Patients and Methods: We perfo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::f33eddfb308904416f78476113b71dbb
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102108
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3102108
BACKGROUND: While immune checkpoint inhibitors (ICIs) are approved in the first-line (1L) setting for cisplatin-unfit patients with programmed death-ligand 1 (PD-L1)-high tumors or for platinum (cisplatin/carboplatin)-unfit patients, response rates r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::b79988d49bdf9ab287be2569a1e7d45b
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3119600
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3119600